SC-AMBIOPHARM
AmbioPharm Inc. a leading supplier of peptide active pharmaceutical ingredients has recently opened its new manufacturing and quality control facilities at its headquarters in South Carolina. “The new buildings were completed in April and qualified by May 15, 2020 expanding our peptide manufacturing capacity,” stated Dr. Chris J. Bai, CEO. “The new buildings add nearly 56,000 sq. ft of production space to our current footprint in South Carolina. In the near future, our subsidiary site in Shanghai will also complete a new campus of 350,000 sq. ft. later this year,” stated Dr. Bai.
“As the world battles the Covid-19 pandemic, it has become increasingly apparent that no single solution will suffice for patients who are fighting the disease. Peptide approaches have been recently advanced for potential vaccine development, diagnostic testing and as therapeutic agents to help ameliorate the cytokine storm,” stated Dr. Michael W. Pennington, CSO. “Furthermore, we believe that science will prove to be the Achilles’ heel of the virus, and the world will recover more quickly as better therapies become available,” added Dr. Pennington.
AmbioPharm Inc. is uniquely positioned to help companies that are developing peptide-based approaches targeting the virus. As the company with the world’s largest cGMP peptide manufacturing capacity, AmbioPharm Inc. has a very unique business model which helps us to produce peptides of both high quality and purity with very economical cost. AmbioPharm Inc. can be contacted through our website if you have a project which requires our services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630006013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 45.4 Million Elevance Health Members22.10.2025 14:00:00 CEST | Press release
Coverage effective across Elevance Health’s commercial, Medicare, and Medicaid plans in 14 states Decision informed by growing clinical evidence, with additional real-world and long-term safety and efficacy data now being collected across global centers HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced that Elevance Health (formerly Anthem, Inc.) has issued a positive medical policy for the use of histotripsy in the treatment of liver tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022130560/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics The policy, effective October 21, 2025, expands insurance coverage across Elevance Health’s commercial, Medicare, and Medicaid plans in 14 states, including California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virgin
Regula Launches Knowledge Hub to Advance Understanding of Digital ID22.10.2025 14:00:00 CEST | Press release
Regula, a leading developer of identity verification (IDV) solutions and forensic devices, has unveiled a new online resource center, The Road to Digital ID. This knowledge hub is designed to provide a clear, structured guide to what digital identity is, how it’s verified, what risks it brings, and what opportunities it creates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022763979/en/ Regula’s knowledge hub, The Road to Digital ID, comprises educational content, research findings, tech know-how, and general-interest articles. Across the world, governments and businesses are increasingly embracing digital identity frameworks. In the UK, for example, the government recently announced a new digital ID scheme that will be mandatory for Right to Work checks. While hailed as a modernization effort, it has also reawakened debates about privacy, trust, and governance. Digital ID nailed down Although nearly half of organizatio
AI and Data Leaders NVIDIA, AMD, Snowflake, and Databricks Invest in Uniphore’s Series F to Accelerate Its Leadership in Business AI22.10.2025 13:30:00 CEST | Press release
Uniphore, the Business AI company, today announced the close of its $260 million Series F round. NVIDIA, AMD, Snowflake, and Databricks invested in the round and were joined by financial and sovereign investors including NEA, March Capital, BNF Capital, National Grid Partners, and Prosperity7 Ventures. The new capital will accelerate innovation on its AI and data platform – Business AI Cloud – while deepening its ecosystem. “Our Series F raise marks an exciting milestone for Uniphore. It is unlike most fundraises because, in addition to top-tier financial investors, we are joined by the world’s top AI and data companies,” said Umesh Sachdev, Co-founder and CEO, Uniphore. “This unique combination of capital and strategic alignment validates Uniphore’s position as the Business AI leader. We are seeing exponential adoption from Fortune 500 and other large companies, and this investment allows us to deliver even greater impact and accelerate innovation on behalf of our customers worldwide.
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 622.10.2025 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2025 financial results on Thursday, November 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting developme
Diligent and Persefoni Form Strategic Partnership to Support Clients in Navigating Sustainability Reporting With Confidence22.10.2025 12:00:00 CEST | Press release
Diligent, the AI leader in governance, risk and compliance SaaS solutions, and Persefoni AI, Inc., a leading Sustainability Management SaaS and AI platform for companies and financial institutions, today announced a strategic partnership to lead the way in sustainability by ensuring clients have the best tools and support to meet their strategic goals and navigate an increasingly complex sustainability landscape with confidence. As part of the agreement, Diligent will transition its carbon accounting clients to Persefoni’s market-leading platform and take an equity position in Persefoni, reinforcing a long-term commitment to innovation in ESG. This partnership ensures Diligent clients benefit from best-in-class capabilities in carbon footprint management, including advanced Scope 3 supply chain sustainability solutions and AI-powered disclosure readiness. "Diligent is committed to providing our customers with the best solutions available to meet today’s needs while preparing for tomorr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom